Vijay M Patil et al., 2020-07: Phase 1 study of mebendazole added to re-irradiation, temozolomide or lomustine in recurrent glioblastoma, which set its dose levels explicitly to exceed the in vitro IC50.
The reported IC50 in a human glioma cell line for mebendazole was 0.1 µmol/L and thus the objective was to achieve a brain concentration of mebendazole above this level.
Vijay M Patil et al., 2020-07: Phase 1 study of mebendazole added to re-irradiation, temozolomide or lomustine in recurrent glioblastoma, which set its dose levels explicitly to exceed the in vitro IC50. Study type: phase 1 accelerated titration (N=11). Country: India (Tata Memorial Centre, Mumbai). Dose: mebendazole escalated 100, 200, 400, 800 and 1600 mg three times daily; recommended phase 2 dose 4800 mg/day with temozolomide and 2400 mg/day with CCNU. Funder: not stated in the record. Declared conflicts: 'None.' Comparator: none (single-arm dose finding). The same paper gives the human plasma figures used for the lab-versus-blood comparison: chronic 1.5 g/day gives a mean peak of 0.28 micromol/L and 40 mg/kg/day gives 0.47 micromol/L, against an in vitro IC50 of 0.1 micromol/L and a brain-to-plasma ratio of 0.6-0.8 for polymorphs B and C. This is the highest published long-term human dosing schedule in the record. Also filed as MBC-10 (claims C2, C7).
